关于公司
- 法定名称: Regenix drugs Ltd
- 注册国家: India
- 地址: B-26, Phase -II, Zone B ,MEPZ -SEZ, Tambaram, , Tamilnadu
- 员工人数: 50 - 99
- 成立年份: 2007
描述:
Regenix is a biosimilar injection formulation and fill-finish manufacturing facility located in Chennai, India. A WHO-GMP-accredited, state-of-the-art facility spanning 30,000 square feet, designed to the latest GMP regulatory standards to fill sterile products in vials, pre-filled syringes and cartridges, the company's current CTD-format dossier product list includes human insulin injection (R, 30/70 and NPH), Insulin Glargine, Liraglutide and Enoxaparin Sodium injections.
业务活动
成品制剂
制造商
生物制药产品
制造商
ATC(解剖学-治疗学-化学)分类系统
制造商
销售市场
- South Asia: Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka, Afghanistan, Iran
- Mainland Southeast Asia: Cambodia, Lao People's Democratic Republic, Myanmar, Thailand, Viet Nam, Brunei Darussalam, Indonesia, Malaysia, Philippines, Timor-Leste, Singapore
- Northern Europe: Iceland, Norway, United Kingdom
- Southern Europe: Albania, Andorra, Bosnia and Herzegovina, North Macedonia, Montenegro, Serbia, Vatican City
主要产品/服务
我们的产品与服务
Certifications
GMP
ISO
Proofs
CPHI Milan 2026
10/2026 – 10/2026
CPHI Milan 2026
评分
(0)
(0)
(0)
(0)
(0)
评论
筛选：
排序方式：
暂无评论。
留下您的评分和评论